Fig 1: Correlation between BTG3 protein expression status and prognosis of ovarian carcinoma patients. Kaplan–Meier curves for overall (a) or disease-free (b) survival rate of patients with ovarian carcinomas according to BTG3 protein expression. It was indicated that patients with lower BTG3 expression have more likely shorter overall survival and disease-free time (overall survival time, p = 0.020; disease-free time, p = 0.021)
Fig 2: The correlation of BTG3 mRNA expression with tumorigenesis and aggressive features of ovarian carcinoma. Real-time RT–PCR was employed to amplify BTG3 mRNA in 121 ovarian samples (a). BTG3 mRNA level was higher in ovarian normal tissue (No, n = 17) and benign tumor (Be, n = 12) than that in borderline tumor (Bor, n = 6), primary carcinoma (Ca, n = 65), or metastatic carcinoma in omentus (Om, n = 21) (p < 0.05, b). No statistical differences were found between ovarian normal tissue (No) and benign tumor (Be), or among borderline tumor (Bor), primary carcinoma (Ca), or metastatic carcinoma in omentus (Om). Well-differentiated carcinoma showed higher BTG3 mRNA expression in comparison with moderately and poorly differentiated ones (p < 0.05, c). BTG3 mRNA displayed lower expression in advanced FIGO staging EOC (p < 0.05, d)
Fig 3: The correlation of BTG3 protein expression with tumorigenesis and aggressive features of ovarian carcinoma. Western blot was employed to valuate BTG3 protein expression in 78 ovarian samples (a). BTG3 was higher in ovarian normal tissue (n = 9) and benign tumor (n = 10) than that in EOCs (n = 59) (p < 0.05, b). Well-differentiated and moderately differentiated EOC showed higher BTG3 expression in comparison with poorly differentiated ones (p = 0.045, c). No statistical difference of BTG3 expression was found between FIGO I/II and FIGO III/IV staging (p > 0.05, d)
Supplier Page from MilliporeSigma for Anti-BTG3 antibody produced in rabbit